Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season Wednesday September 10, 9:35 pm ET BEIJING, Sept. 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vac

Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu

September 10, 9:35 pm ET

Sept. 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a

leading provider of vaccines in China, today announced the market launch of

Anflu , a seasonal influenza vaccine, for 2008-2009 Flu Season. Developed and

manufactured by Sinovac, Anflu is the only split influenza vaccine produced

without preservatives in China. Sinovac is undertaking the sales and marketing

program utilizing its established sales force to promote the adult dosage form

the virus strain for the Northern Hemisphere recommended by the World Health

Organization, Sinovac has commenced the production of Anflu for the annual flu

season based on its 2008-2009 production plan. The Chinese authorities have

recently completed the review of the batch release process and approved the

vaccine for launch. In August 2008, the China CDC issued the 2008 "Guidelines

for Influenza Prevention and Control Technology" that highlighted the positive

public health implications of receiving the seasonal flu vaccine, the target

population and the extension of the vaccination duration. As an amendment to the

2007 version, the 2008 guidance expanded the recommended vaccination population

to include people living in senior homes, nursing homes and chronic disease

nursing facilities, along with childcare providers who are looking after infants

less than six month in age.

past year, Sinovac has expanded its manufacturing capacity with the construction

of a pandemic influenza vaccine production line with annual capacity of 20

million doses using the grant from China's National Development and Reform

Commission. The production line includes state-of-the-art automated production

equipment along with an expanded packaging capability and affords Sinovac the

ability to produce up to five million doses of Anflu . By leveraging the latest

production technology, the quality of the Anflu vaccine will be

with its efforts incorporate the latest technology, Sinovac has introduced new

insulation packaging to facilitate vaccine distribution. Based on customer

feedback, the packaging features color-coded insulated packaging that

effectively utilizes ice to maintain the desired temperature. The updated

packaging enables the shipping of 50 or 100 doses.

Weidong Yin, Chairman, President and CEO, commented, "We are very pleased to

launch Anflu in China for the 2008 - 2009 seasonal influenza season. By

utilizing our state-of-the-art production capability, we are well positioned to

deliver our adult dosage formulation to our target market in

Biotech Ltd. is a China-based biopharmaceutical company that focuses on the

research, development, manufacture and commercialization of vaccines that

protect against human infectious diseases. Sinovac's commercialized vaccines

include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu

(influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal

Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional

information about Sinovac is available on its website,

http://www.sinovac.com.

To be added to our distribution list, please email:

announcement contains forward-looking statements. These statements are made

under the "safe harbor" provisions of the U.S. Private Securities Litigation

Reform Act of 1995. These forward-looking statements can be identified by words

or phrases such as "will," "expects," "anticipates," "future," "intends,"

"plans," "believes," "estimates" and similar statements. Among other things, the

business outlook and quotations from management in this press release contain

forward-looking statements. Statements that are not historical facts, including

statements about Sinovac's beliefs and expectations, are forward-looking

statements. Forward-looking statements involve inherent risks and uncertainties.

A number of important factors could cause actual results to differ materially

from those contained in any forward-looking statement. Sinovac does not

undertake any obligation to update any forward-looking statement, except as

required under applicable law.

more information, please contact:

Tel: +86-10-8289-0088

Fax: +86-10-6296-6910

Carrington / Janine McCargo

Tel: +1-646-536-7017/7033

scarrington@theruthgroup.com / jmccargo@theruthgroup.com